Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 5/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23680757 | 0.89 | HPGD (0.64) | HPGDMGLLADORA2AGRM5ALDH1A1 | |
| SCHEMBL23680729 | 0.87 | HPGD (0.64) | HPGDMGLLGRM5KDM4EALDH1A1 | |
| SCHEMBL23680707 | 0.86 | HPGD (0.61) | HPGDMGLLADORA2AGRM5 | |
| SCHEMBL23680746 | 0.85 | HPGD (0.66) | HPGDMGLLADORA2AGRM5KDM4E | |
| SCHEMBL23680759 | 0.84 | HPGD (0.77) | HPGDMGLLGRM5 | |
| SCHEMBL23680773 | 0.84 | HPGD (0.63) | HPGDMGLLADORA2AGRM5EGFR | |
| SCHEMBL23680797 | 0.83 | HPGD (0.66) | HPGDMGLLADORA2AGRM5KDM4E | |
| SCHEMBL23680790 | 0.83 | HPGD (0.71) | HPGDMGLLADORA2AKDM4EALDH1A1 | |
| SCHEMBL23680826 | 0.81 | HPGD (0.66) | HPGDMGLLADORA2AALDH1A1 | |
| SCHEMBL23680791 | 0.81 | HPGD (0.74) | HPGDMGLLADORA2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | MYOFORTE THERAPEUTICS, INC. (US) | 2022-05-31 | — | — | US | disclosed |
| WO-2022082009-A1 | INHALED FORMULATIONS OF PGDH INHIBITORS AND METHODS OF USE THEREOF | EPIRIUM BIO INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2021151014-A1 | PGDH INHIBITORS AND METHODS OF MAKING AND USING | MYOFORTE THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345702-B1 | PGDH inhibitors and methods of making and using | HPGD, HPGDS, PTGS1 | HPGD 1/4885MGLL 494/4885ADORA2A 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.